| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 08/01/2002 | WO2002058740A1 Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases |
| 08/01/2002 | WO2002058737A2 Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| 08/01/2002 | WO2002058735A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | WO2002058726A1 Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
| 08/01/2002 | WO2002058725A2 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058714A2 Methods and agents modulating upa/upar activity |
| 08/01/2002 | WO2002058712A2 Probiotic compounds derived from lactobacillus casei strain ke01 |
| 08/01/2002 | WO2002058695A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | WO2002058692A2 Halogenated composition, method for preparing same and uses thereof |
| 08/01/2002 | WO2002058668A2 Artificial tear composition adapted to be used with contact lenses |
| 08/01/2002 | WO2002058629A2 Stable aqueous antimicrobial suspension |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058624A2 In situ generation allicin for the treatment of cancer and infectious diseases |
| 08/01/2002 | WO2002045749A3 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 08/01/2002 | WO2002043651A3 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002032233A3 Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
| 08/01/2002 | WO2002019986A9 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 08/01/2002 | WO2002016437A3 Rhabdovirus-based vectors to express high levels of functional human antibodies |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002004497A3 Multiple antigenic peptides immunogenic against streptococcus pneumoniae |
| 08/01/2002 | WO2002004019A3 Use of strains of the parapox ovis virus against organ fibrosis |
| 08/01/2002 | WO2001096565A3 Binding agents: chimeric ligand/receptor proteins |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001082953A3 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 08/01/2002 | WO2001081325A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 08/01/2002 | WO2001080633A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/01/2002 | WO2001078654A3 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 08/01/2002 | WO2001077157A3 Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv |
| 08/01/2002 | WO2001076606A3 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001070955A3 Identification of essential genes in prokaryotes |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001041800A9 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 08/01/2002 | US20020103377 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms |
| 08/01/2002 | US20020103336 Cloning of chicken anemia dna |
| 08/01/2002 | US20020103262 Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus |
| 08/01/2002 | US20020103247 Indole and dihydroindole derivatives |
| 08/01/2002 | US20020103245 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 08/01/2002 | US20020103234 Heterocycl-containing carboxylic acid derivative and drug containing the same |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103225 Comprises solid amorphous dispersion of compounds such as (2R,4S)4-((3,5-dichloro-benzyl)-methoxycarbonyl-amino)-6,7-dimethoxy-2 -methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester for elevating plasma lipid levels |
| 08/01/2002 | US20020103220 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4- dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors |
| 08/01/2002 | US20020103186 Use against multiply resistant gram positive pathogens; have a diazine moiety attached to the phenyloxazolidinone which is further substituted by heterocyclic, aryl, substituted aryl, heteroaroamatic ring |
| 08/01/2002 | US20020103178 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 08/01/2002 | US20020103171 7-and 9- carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 08/01/2002 | US20020103170 Oxazinoquinolones useful for the treatment of viral infections |
| 08/01/2002 | US20020103148 Vectors comprising SAR elements |
| 08/01/2002 | US20020103114 Administering therapeutically effective amount of bactericidal/permeability-increasing protein product to a human suffering from meningococcemia |
| 08/01/2002 | US20020103104 Administering to individual a antibacterially effective amount of an antagonist that inhibits or an agonist that activates an activity of a signal recognition particle polypeptide |
| 08/01/2002 | US20020102712 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of viral diseases |
| 08/01/2002 | US20020102701 licD1 |
| 08/01/2002 | US20020102609 Antagonists of HMG1 for treating inflammatory conditions |
| 08/01/2002 | US20020102540 Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 08/01/2002 | US20020102537 Retroviral production |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102533 Monitoring activity of viral enzymatic polypeptide; obtain protease, incubate with modulator, monitor adjustment in protease activity |
| 08/01/2002 | US20020102298 Temperature-sensitive liposomal formulation |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020102277 Conserved metalloprotease epitopes |
| 08/01/2002 | US20020102276 For diagnosis, therapy and prophylaxis of Neisseria meningitidis infection; vaccine |
| 08/01/2002 | US20020102270 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 08/01/2002 | US20020102269 Contacting a parental Helicobacter with molecule in biological sample, testing and comparing response to extracellular pH and sensitivity to acidity of parental strain to a strain deficient in UreI; selecting molecule |
| 08/01/2002 | US20020102256 Peptide and polypeptide inhibitors of complement C1s |
| 08/01/2002 | US20020102242 Compositions and methods for administering pneumococcal DNA |
| 08/01/2002 | US20020102235 Novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus |
| 08/01/2002 | US20020102230 Method for inactivating pathogens |
| 08/01/2002 | US20020102223 For treating fungal infections of human fingernails and toenails, and for alleviating other symptoms often associated with such fungal infections |
| 08/01/2002 | DE10101890A1 HPV-spezifische Peptide, die die Bindung von HPV an die Wirtszelle blockieren HPV specific peptides that block the binding of HPV to the host cell |
| 08/01/2002 | DE10101307A1 Fumarsäurederivate als NF-kappaB-Inhibitor Fumaric acid derivatives as NF-kappaB inhibitor |
| 08/01/2002 | CA2792244A1 A method for identification, isolation and production of antigens to a specific pathogen |
| 08/01/2002 | CA2442602A1 Probiotic compounds derived from lactobacillus casei strain ke01 |
| 08/01/2002 | CA2436091A1 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 08/01/2002 | CA2435949A1 Biological organism for preparing pharmaceutical compositions for treating mammals |
| 08/01/2002 | CA2435888A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435776A1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | CA2435647A1 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | CA2435568A1 Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
| 08/01/2002 | CA2435124A1 Formulation of boronic acid compounds |
| 08/01/2002 | CA2435097A1 Peptides exibiting affinity for the viral protein gp120, and use of the se peptides |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2433680A1 Double-stranded rna-mediated gene suppression |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2432096A1 Methods for preparing purified lipopeptides |
| 08/01/2002 | CA2431904A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 08/01/2002 | CA2424402A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 08/01/2002 | CA2421583A1 Oxazolidinones having a benzannulated 6-or 7-membered heterocycle as antibacterial agents |
| 07/31/2002 | EP1227324A2 Har A polypeptides and nucleic acids and related methods and uses thereof |
| 07/31/2002 | EP1227103A2 Ring-expanded nucleosides and nucleotides |
| 07/31/2002 | EP1227097A1 Ucs1025 derivatives |
| 07/31/2002 | EP1227096A1 4-oxoquinolizine antimicrobials having 2-pyridone skeletons as the partial structure |
| 07/31/2002 | EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |